Tag Archive for: immunology

Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic

/in

Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher Bio Follows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine release Commit is poised to nominate its first two clinical development candidates later in 2026 COPENHAGEN, Denmark — March 11, 2026 — Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed […]

Read more

Nucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific Officer

/in

Brings deep expertise in immunology, oncology and pharmacology with a strong track record of advancing innovative pipelines through discovery and translation into the clinic Reflects growing momentum at Nucleome following nomination of first preclinical development candidate for lead candidate NTP464, which is progressing towards IND enabling studies  Oxford, UK, 16 February 2026 – Nucleome Therapeutics […]

Read more

Resolve M Therapeutics exits from stealth

/in

Unique platform designed to engage pro-resolution responses to restore immune homeostasis in inflammatory disorders without broad immuno-suppression. Cambridge, MA, USA, January 22, 2026 – Resolve M Therapeutics, Inc., the biotech aiming to build the world’s first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its […]

Read more

Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell

/in

Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living cells at base pair resolution for the first time, pioneering a new approach to identify new drug targets from human genetics   Oxford, UK, 6 November 2025 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), an immunology company tackling the root causes of […]

Read more

Kling Bio Announces Collaboration with Sanofi for Accelerated Discovery of Neutralizing Antibodies

/in

Leverages Kling’s technology to discover hard-to-find, immuno-functional antibodies from immortalized human B cells Accelerating discovery of first-in-class antibodies to transform disease prevention and treatment Amsterdam, NLD – 24 July 2025 – Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announced it has entered into a […]

Read more